Dr. James "Jay" Bradner joined Amgen in 2023 as executive vice president, Research and Development, and chief scientific officer. He is responsible for advancing Amgen's pipeline, which includes potential first-in-class or best-in-class medicines in all stages of development across the company's four therapeutic areas of focus: oncology, inflammation, general medicine and rare disease, in addition to biosimilars. He is also responsible for Amgen's worldwide research efforts.
Prior to joining Amgen, Dr. Bradner served as President of the Novartis Institutes for BioMedical Research, where he was a member of the Executive Committee of Novartis. His research and leadership have contributed to numerous development programs, multiple investigational new drug applications and positive proof-of-concept studies in clinical investigation. He also has been a clinician at the Dana-Farber Cancer Institute and an associate professor at Harvard Medical School. As an entrepreneur, he co-founded and built several biotechnology startups. Additionally, he has co-authored dozens of scientific publications and is a named inventor on numerous U.S. patent applications.
Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed his residency in Medicine at Brigham & Women's Hospital, his fellowship in Medical Oncology and Hematology at the Dana-Farber Harvard Cancer Center, and his postdoctoral training in Chemistry and Chemical Biology at Harvard University.